5-Nitro-3-(2-(4-phenylthiazol-2-yl)hydrazineylidene)indolin-2-one derivatives inhibit HIV-1 replication by a multitarget mechanism of action

Front Cell Infect Microbiol. 2023 Jun 23:13:1193280. doi: 10.3389/fcimb.2023.1193280. eCollection 2023.

Abstract

In the effort to identify and develop new HIV-1 inhibitors endowed with innovative mechanisms, we focused our attention on the possibility to target more than one viral encoded enzymatic function with a single molecule. In this respect, we have previously identified by virtual screening a new indolinone-based scaffold for dual allosteric inhibitors targeting both reverse transcriptase-associated functions: polymerase and RNase H. Pursuing with the structural optimization of these dual inhibitors, we synthesized a series of 35 new 3-[2-(4-aryl-1,3-thiazol-2-ylidene)hydrazin-1-ylidene]1-indol-2-one and 3-[3-methyl-4-arylthiazol-2-ylidene)hydrazine-1-ylidene)indolin-2-one derivatives, which maintain their dual inhibitory activity in the low micromolar range. Interestingly, compounds 1a, 3a, 10a, and 9b are able to block HIV-1 replication with EC50 < 20 µM. Mechanism of action studies showed that such compounds could block HIV-1 integrase. In particular, compound 10a is the most promising for further multitarget compound development.

Keywords: IN inhibitors; RT inhibitors; antiviral agents; drug design; multitarget inhibitors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • HIV Reverse Transcriptase / chemistry
  • HIV Reverse Transcriptase / metabolism
  • HIV-1*
  • Oxindoles
  • Reverse Transcriptase Inhibitors* / chemistry
  • Reverse Transcriptase Inhibitors* / pharmacology
  • Structure-Activity Relationship
  • Virus Replication

Substances

  • Reverse Transcriptase Inhibitors
  • indolin-2-one
  • Oxindoles
  • HIV Reverse Transcriptase

Grants and funding

a) This study was financially supported by Regione Autonoma della Sardegna (RAS) (LR 07/2017, annualità 2017) grant no. RASSR17032. b) This research was supported by EU funding within the NextGenerationEU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project no. PE00000007, INF-ACT).